# US 2026/0086085 A1 · Methods of analyzing lipid nanoparticles in physiological fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0086085 A1
- Document ID: US20260086085A1
- Status: Published application
- Kind: A1
- Application number: 19/113,575
- Filed: 2023-10-16
- Published: 2026-03-26
- Earliest claimed: 2022-10-17
- Assignees: Agilent Technologies, Inc.
- Applicants: Agilent Technologies, Inc.
- Inventors: Brian Liau; Ravindra Gudihal
- Web page: https://patentgrep.com/patent/US20260086085A1

## CPC

- G01N 15/0211: {Investigating a scatter or diffraction pattern}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- B01D 15/1871: {placed in series}
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- G01N 15/1456: {without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals}
- G01N 30/14: by elimination of some components
- G01N 30/74: Optical detectors {(measurement of intensity, velocity, spectral content, polarisation, or phase of infrared, visible or ultraviolet light G01J)}
- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2015/0038: {Investigating nanoparticles}
- G01N 2015/0222: {from dynamic light scattering, e.g. photon correlation spectroscopy}
- G01N 2015/1486: {Counting the particles}
- G01N 2015/1493: {Particle size}
- G01N 2030/8813: {biological materials}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.

## Claims

### Claim 1

A method of determining the stability of a lipid nanoparticle (LNP) in a subject, comprising:
acquiring a first sample comprising the LNP from the subject;
subjecting the first sample to a size-exclusion chromatography (SEC);
acquiring a multi angle light scattering (MALS) signal from the first sample;
acquiring a second sample comprising the LNP from the subject;
subjecting the second sample to the SEC;
acquiring a second MALS signal from the second sample; and
comparing the first MALS signal and the second MALS signal,
wherein the first and second samples comprise a physiological fluid, and wherein the comparison between the first MALS signal and the second MALS signal is indicative of the stability of the LNP in the subject,
thereby determining the stability of the LNP in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the SEC is performed in a dual-column configuration using a first column with a first average pore size and a second column with a second average pore size, and wherein the first average pore size is greater than the second average pore size.

### Claim 3 (depends on 2)

The method of claim 2, wherein the first average pore size has a molecular weight cut-off (MWCO) of 1 MDa to 20 MDa, and wherein the second average pore size has an MWCO of 0.1 MDa to 10 MDa.

### Claim 4 (depends on 1)

The method of claim 1, wherein the SEC is performed using a polymer-based column having a length of about 100 mm to 1000 mm with a bio-compatible buffer system.

### Claim 5 (depends on 1)

The method of claim 1, wherein the MALS is performed at a scattering angle of 15° and 90° and using a laser wavelength of about 500 nm to 800 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the MALS is performed using a sample cell volume of about 1 μL to 50 μL and a scattering volume of about 0.001 μL to 0.1 μL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the MALS is performed at a temperature range of about 20° C. to 70° C. with a temperature stability of no more than ±1° C.

### Claim 8 (depends on 1)

The method of claim 1, wherein the MALS is performed at a pH range of about 1-12.

### Claim 9 (depends on 1)

The method of claim 1, wherein the size of the LNP is determined.

### Claim 10 (depends on 1)

The method of claim 1, wherein the molecular weight (MW) of the LNP is determined.

### Claim 11 (depends on 1)

The method of claim 1, wherein the half-life of the LNP is determined.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method does not comprise a step of recovering the LNP by ultracentrifugation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method does not comprise a step of diluting the sample to remove a high molecular weight plasma or serum component.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method does not comprises a step of labeling the LNP with a fluorophore.

### Claim 15 (depends on 1)

The method of claim 1, wherein the LNP is loaded with a nucleic acid.

### Claim 16 (depends on 1)

The method of claim 1, wherein the nucleic acid is an mRNA, a small interfering RNA (siRNA), an antisense oligonucleotide (ASO), or a DNA.

### Claim 17 (depends on 16)

The method of claim 16, wherein the physiological fluid is plasma, serum, or blood.

### Claim 18 (depends on 1)

A system comprising a processor configured to perform the method of claim 1.

### Claim 19

A method of determining the purity of a lipid nanoparticle (LNP) in a sample, comprising:
acquiring a first aliquot of the sample;
subjecting the first aliquot to a size-exclusion chromatography (SEC);
acquiring a multi angle light scattering (MALS) signal from the first aliquot;
acquiring a second aliquot of the sample;
subjecting the second aliquot to the SEC;
acquiring a second MALS signal from the second aliquot; and
comparing the first MALS signal and the second MALS signal to determine the stability of the LNP in the sample, which is indicative of the purity of the LNP in the sample,
wherein the sample comprises a physiological fluid,
thereby determining the purity of the LNP in the sample.

### Claim 20

A method of monitoring a process of manufacturing a lipid nanoparticle (LNP), comprising:
acquiring a first sample comprising an LNP from the process of manufacturing the LNP;
subjecting the first sample to a size-exclusion chromatography (SEC); and
acquiring a multi angle light scattering (MALS) signal from the first sample,
acquiring a second sample comprising the LNP from the process of manufacturing the LNP;
subjecting the second sample to the SEC; and
acquiring a second MALS signal from the second sample,
wherein the first and second samples comprise a physiological fluid,
thereby monitoring the process of manufacturing the LNP.
